Loading...

NewLink Genetics

DB:4NX
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4NX
DB
$67M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. The last earnings update was 111 days ago. More info.


Add to Portfolio Compare Print
  • NewLink Genetics has significant price volatility in the past 3 months.
4NX Share Price and Events
7 Day Returns
22.5%
DB:4NX
-1.2%
DE Biotechs
1.9%
DE Market
1 Year Returns
-72.1%
DB:4NX
-4.3%
DE Biotechs
-11%
DE Market
4NX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NewLink Genetics (4NX) 22.5% 26.4% -6% -72.1% -92% -95.6%
DE Biotechs -1.2% -5.4% -2.7% -4.3% 88.2% 7.8%
DE Market 1.9% 2.1% 1.8% -11% 15.5% 6.5%
1 Year Return vs Industry and Market
  • 4NX underperformed the Biotechs industry which returned -4.3% over the past year.
  • 4NX underperformed the Market in Germany which returned -11% over the past year.
Price Volatility
4NX
Industry
5yr Volatility vs Market

Value

 Is NewLink Genetics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NewLink Genetics. This is due to cash flow or dividend data being unavailable. The share price is €1.58.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NewLink Genetics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NewLink Genetics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4NX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-1.53
NasdaqGM:NLNK Share Price ** NasdaqGM (2019-02-21) in USD $1.81
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 23.99x
Germany Market PE Ratio Median Figure of 420 Publicly-Listed Companies 18.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NewLink Genetics.

DB:4NX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:NLNK Share Price ÷ EPS (both in USD)

= 1.81 ÷ -1.53

-1.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NewLink Genetics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • NewLink Genetics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NewLink Genetics's expected growth come at a high price?
Raw Data
DB:4NX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
2.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 20 Publicly-Listed Biotechs Companies 1.44x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NewLink Genetics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NewLink Genetics's assets?
Raw Data
DB:4NX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $3.28
NasdaqGM:NLNK Share Price * NasdaqGM (2019-02-21) in USD $1.81
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 2.55x
Germany Market PB Ratio Median Figure of 566 Publicly-Listed Companies 1.79x
DB:4NX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:NLNK Share Price ÷ Book Value per Share (both in USD)

= 1.81 ÷ 3.28

0.55x

* Primary Listing of NewLink Genetics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NewLink Genetics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess NewLink Genetics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NewLink Genetics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NewLink Genetics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NewLink Genetics expected to grow at an attractive rate?
  • Unable to compare NewLink Genetics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare NewLink Genetics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • NewLink Genetics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:4NX Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4NX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 2.8%
DB:4NX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 12.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 29.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 25.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 9.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4NX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4NX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 57 -36 1
2022-12-31 6 -63 1
2021-12-31 8 -59 1
2020-12-31 8 -55 1
2019-12-31 48 -57 1
2018-12-31 12 -54 3
DB:4NX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 22 -54 -57
2018-06-30 28 -46 -70
2018-03-31 36 -50 -69
2017-12-31 29 -48 -72
2017-09-30 31 -48 -72
2017-06-30 41 -54 -67
2017-03-31 33 -59 -82
2016-12-31 36 -66 -85
2016-09-30 31 -57 -93
2016-06-30 30 -51 -94
2016-03-31 35 -41 -75
2015-12-31 69 -24 -40

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NewLink Genetics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • NewLink Genetics's revenue is expected to grow by 12.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4NX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from NewLink Genetics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4NX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.67 -0.67 -0.67 1.00
2022-12-31 -1.19 -1.19 -1.19 1.00
2021-12-31 -1.48 -1.48 -1.48 1.00
2020-12-31 -1.46 -1.24 -1.68 2.00
2019-12-31 -1.54 -1.49 -1.58 2.00
2018-12-31 -1.50 -1.45 -1.59 3.00
DB:4NX Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -1.53
2018-06-30 -1.98
2018-03-31 -2.08
2017-12-31 -2.30
2017-09-30 -2.44
2017-06-30 -2.29
2017-03-31 -2.83
2016-12-31 -2.94
2016-09-30 -3.23
2016-06-30 -3.25
2016-03-31 -2.62
2015-12-31 -1.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NewLink Genetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NewLink Genetics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NewLink Genetics has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NewLink Genetics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NewLink Genetics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NewLink Genetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NewLink Genetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NewLink Genetics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NewLink Genetics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NewLink Genetics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4NX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 22.37 -56.71 29.68
2018-06-30 27.73 -69.94 29.70
2018-03-31 35.85 -69.35 30.68
2017-12-31 28.71 -71.95 30.63
2017-09-30 31.32 -71.77 31.12
2017-06-30 41.18 -66.69 31.56
2017-03-31 32.82 -82.35 31.80
2016-12-31 35.77 -85.16 32.73
2016-09-30 30.72 -93.22 33.23
2016-06-30 29.58 -93.59 33.36
2016-03-31 35.01 -75.29 31.49
2015-12-31 68.50 -40.38 30.69
2015-09-30 230.09 101.21 31.29
2015-06-30 218.69 111.52 28.84
2015-03-31 211.45 116.44 24.44
2014-12-31 172.59 96.02 19.33
2014-09-30 3.64 -32.04 14.04
2014-06-30 1.11 -34.57 11.37
2014-03-31 1.13 -32.48 10.77
2013-12-31 1.09 -31.18 9.52
2013-09-30 1.10 -29.45 8.63
2013-06-30 1.16 -27.18 7.76
2013-03-31 1.52 -26.41 7.65
2012-12-31 1.69 -23.32 7.11
2012-09-30 1.69 -22.81 7.13
2012-06-30 1.79 -20.95 6.84 -6.98
2012-03-31 1.74 -19.03 5.82 -3.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NewLink Genetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NewLink Genetics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NewLink Genetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NewLink Genetics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NewLink Genetics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NewLink Genetics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NewLink Genetics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NewLink Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NewLink Genetics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NewLink Genetics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1015.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NewLink Genetics Company Filings, last reported 4 months ago.

DB:4NX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 122.20 0.13 122.06
2018-06-30 124.95 0.17 137.07
2018-03-31 137.95 0.20 143.89
2017-12-31 151.56 0.27 158.71
2017-09-30 106.46 0.33 120.70
2017-06-30 102.60 0.40 107.78
2017-03-31 114.35 0.46 118.24
2016-12-31 129.47 0.52 131.49
2016-09-30 138.28 0.58 148.28
2016-06-30 149.34 0.64 160.53
2016-03-31 176.81 0.70 177.98
2015-12-31 195.77 0.94 197.80
2015-09-30 207.41 0.99 200.36
2015-06-30 225.76 1.04 207.58
2015-03-31 232.83 1.09 214.37
2014-12-31 196.94 1.13 202.80
2014-09-30 70.39 1.18 67.71
2014-06-30 72.60 1.13 77.11
2014-03-31 79.83 1.18 83.96
2013-12-31 58.33 1.22 61.54
2013-09-30 47.35 1.27 51.96
2013-06-30 54.36 1.32 59.29
2013-03-31 59.99 1.31 64.03
2012-12-31 17.93 1.38 21.74
2012-09-30 23.22 1.45 28.30
2012-06-30 28.23 1.06 31.07
2012-03-31 32.80 1.10 35.76
  • NewLink Genetics's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (2.7% vs 0.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NewLink Genetics has sufficient cash runway for 2.3 years based on current free cash flow.
  • NewLink Genetics has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 40.9% each year.
X
Financial health checks
We assess NewLink Genetics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NewLink Genetics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NewLink Genetics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NewLink Genetics dividends. Estimated to be 0% next year.
If you bought €2,000 of NewLink Genetics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NewLink Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NewLink Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4NX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 332 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4NX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NewLink Genetics has not reported any payouts.
  • Unable to verify if NewLink Genetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NewLink Genetics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NewLink Genetics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of NewLink Genetics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess NewLink Genetics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NewLink Genetics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NewLink Genetics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NewLink Genetics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Charles Link
COMPENSATION $3,391,817
AGE 59
TENURE AS CEO 16.1 years
CEO Bio

Dr. Charles J. Link, Jr., M.D. Co-founded NewLink Genetics Corporation in 1999. Dr. Link has been Chief Executive Officer and Chief Scientific Officer of NewLink Genetics Corporation since 2003 and 1999 respectively. Dr. Link has been Chairman and Director of NewLink Genetics Corporation since 1999. Dr. Link serves as a Medical Director of the Bone Marrow Transplantation and Gene Therapy Unit of the Iowa Methodist Medical Center in Des Moines, Iowa and Director of the Gene Therapy Program, Human Gene Therapy Research Institute, also of Des Moines. He serves as a Member of Scientific Advisory Board of OptiMEMS, Inc. He has authored over forty publications. Dr. Link received M.D. with Honours from the Stanford University School of Medicine in Palo Alto, California and B A from the Stanford University.

CEO Compensation
  • Charles's compensation has been consistent with company performance over the past year.
  • Charles's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the NewLink Genetics management team in years:

4.1
Average Tenure
52
Average Age
  • The tenure for the NewLink Genetics management team is about average.
Management Team

Charles Link

TITLE
Co-Founder
COMPENSATION
$3M
AGE
59
TENURE
16.1 yrs

Nick Vahanian

TITLE
Co-Founder
COMPENSATION
$3M
AGE
51
TENURE
10.1 yrs

Brian Wiley

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
50
TENURE
4.1 yrs

Gene Kennedy

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
49
TENURE
1.3 yrs

Carl Langren

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$843K
AGE
63
TENURE
0.6 yrs

Lisa Miller

TITLE
Director of Investor Relations

Jun Zhao

TITLE
Vice President of Quality & Compliance
TENURE
4.1 yrs

Brad Powers

TITLE
General Counsel
TENURE
0.6 yrs

Mario Mautino

TITLE
Senior VP of Drug Discovery & Intellectual Property Officer
AGE
52

Tom Monath

TITLE
Chief Scientific Officer & COO of Infectious Disease Division
AGE
77
Board of Directors Tenure

Average tenure and age of the NewLink Genetics board of directors in years:

4.8
Average Tenure
58
Average Age
  • The tenure for the NewLink Genetics board of directors is about average.
Board of Directors

Charles Link

TITLE
Co-Founder
COMPENSATION
$3M
AGE
59
TENURE
20.1 yrs

Nick Vahanian

TITLE
Co-Founder
COMPENSATION
$3M
AGE
51
TENURE
3.3 yrs

Tom Raffin

TITLE
Lead Director
COMPENSATION
$255K
AGE
71

Lota Zoth

TITLE
Director
COMPENSATION
$232K
AGE
58
TENURE
6.3 yrs

Ernest Talarico

TITLE
Director
COMPENSATION
$225K
AGE
47
TENURE
20.1 yrs

Chad Johnson

TITLE
Director
AGE
39
TENURE
0.9 yrs

Matt Sherman

TITLE
Director
AGE
62
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NewLink Genetics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NewLink Genetics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia. The company is also developing NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a clinical stage indoleamine-2, 3-dioxygenase pathway inhibitor. In addition, it is developing tergenpumatucel-L and dorgenmeltucel-L that are in Phase II clinical trials for treating patients with advanced lung cancer and melanoma; and CRLX101 and CRLX301, which are in early clinical development to treat patients with advanced solid malignancies. The company has strategic collaboration agreement with AstraZeneca to evaluate the combination of indoximod and durvalumab, an anti-PD-L1 monoclonal antibody for treating patients with metastatic pancreatic cancer; Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe and Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Details
Name: NewLink Genetics Corporation
4NX
Exchange: DB
Founded: 1999
$59,446,318
37,224,606
Website: http://www.newlinkgenetics.com
Address: NewLink Genetics Corporation
2503 South Loop Drive,
Suite 5100,
Ames,
Iowa, 50010,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM NLNK Common Stock Nasdaq Global Market US USD 14. Nov 2011
DB 4NX Common Stock Deutsche Boerse AG DE EUR 14. Nov 2011
Number of employees
Current staff
Staff numbers
76
NewLink Genetics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/21 21:53
End of day share price update: 2019/02/21 00:00
Last estimates confirmation: 2019/01/03
Last earnings filing: 2018/11/02
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.